Suzhou Ribo Life Science Co., Ltd. (hereinafter referred to as "Ribo") announced that the company will present the preclinical and latest clinical results of its siRNA drug RBD1016 for the treatment of HBV and the preclinical results of its siRNA drug RBD1072 for the treatment of NASH at the 2023 Annual Meeting of the European Association for the Study of the Liver (EASL2023) to be held in Vienna, Austria, in June this year. The EASL Annual Meeting is the largest and most influential conference in the field of liver diseases, attracting thousands of professionals from all around the world every year.

RBD1016 has completed safety, tolerability, and pharmacokinetic studies in healthy volunteers, and is currently being studied for safety, tolerability, pharmacokinetics, and preliminary efficacy in chronic hepatitis B (CHB) patients in single ascending doses (SAD) and multiple ascending doses (MAD) studies. The latest clinical study results of RBD1016 will be released at this conference.

Non-clinical efficacy, pharmacokinetic, and safety data of RBD1016 will also be presented at this conference, including the high-potency and long-lasting reduction of Hepatitis B virus surface antigen (HBsAg) in mouse models, the significant enhancement of HBV DNA suppression after combination therapy with the first-line drug, entecavir (ETV), and the production and accumulation of hepatitis B virus surface antibody (HBsAb) observed after monotherapy.

In addition, the preclinical results of RBD1072 (an HSD17B13 silencing siRNA) in NASH mouse models in terms of effect on steatosis and fibrosis, will be released for the first time at the conference.

Both RBD1016 and RBD1072 are GalNAc-siRNA drugs developed using Ribo's proprietary liver-targeting delivery technology platform, RIBO-GalSTAR^TM. Currently, four GalNAc-siRNA drugs based on this platform have entered the clinical development stage.